Literature DB >> 23022398

NMDA receptor blockade impairs the muscarinic conversion of sub-threshold transient depression into long-lasting LTD in the hippocampus-prefrontal cortex pathway in vivo: correlation with γ oscillations.

Cleiton Lopes-Aguiar1, Lezio Soares Bueno-Junior, Rafael Naime Ruggiero, Rodrigo Neves Romcy-Pereira, João Pereira Leite.   

Abstract

Cholinergic fibers from the brainstem and basal forebrain innervate the medial prefrontal cortex (mPFC) modulating neuronal activity and synaptic plasticity responses to hippocampal inputs. Here, we investigated the muscarinic and glutamatergic modulation of long-term depression (LTD) in the intact projections from CA1 to mPFC in vivo. Cortical-evoked responses were recorded in urethane-anesthetized rats for 30 min during baseline and 4 h following LTD. In order to test the potentiating effects of pilocarpine (PILO), independent groups of rats received either a microinjection of PILO (40 nmol; i.c.v.) or vehicle, immediately before or 20 min after a sub-threshold LTD protocol (600 pulses, 1 Hz; LFS600). Other groups received either an infusion of the selective NMDA receptor antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900). Our results show that PILO converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that NMDA receptor pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO. In addition, AP7 effectively blocked the long-lasting LTD induced by LFS900. Therefore, our findings suggest that the glutamatergic co-activation of prefrontal neurons is important for the effects of PILO on mPFC synaptic depression, which could play an important role in the control of executive and emotional functions.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23022398     DOI: 10.1016/j.neuropharm.2012.09.013

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

1.  The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.

Authors:  Ayan Ghoshal; P Jeffrey Conn
Journal:  Future Neurol       Date:  2015

2.  Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model.

Authors:  A Ghoshal; J M Rook; J W Dickerson; G N Roop; R D Morrison; N Jalan-Sakrikar; A Lamsal; M J Noetzel; M S Poslusney; M R Wood; B J Melancon; S R Stauffer; Z Xiang; J S Daniels; C M Niswender; C K Jones; C W Lindsley; P J Conn
Journal:  Neuropsychopharmacology       Date:  2015-06-25       Impact factor: 7.853

3.  Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 positive allosteric modulator.

Authors:  Marie Pollard; Jose Manuel Bartolome; P Jeffrey Conn; Thomas Steckler; Hamdy Shaban
Journal:  J Psychopharmacol       Date:  2014-07-16       Impact factor: 4.153

4.  Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256.

Authors:  Michael D Grannan; Catharine A Mielnik; Sean P Moran; Robert W Gould; Jacob Ball; Zhuoyan Lu; Michael Bubser; Amy J Ramsey; Masahito Abe; Hyekyung P Cho; Kellie D Nance; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  ACS Chem Neurosci       Date:  2016-10-05       Impact factor: 4.418

5.  Acetazolamide potentiates the afferent drive to prefrontal cortex in vivo.

Authors:  Lezio S Bueno-Junior; Rafael N Ruggiero; Matheus T Rossignoli; Elaine A Del Bel; Joao P Leite; Osvaldo D Uchitel
Journal:  Physiol Rep       Date:  2017-01-13

6.  Interaction between hippocampal-prefrontal plasticity and thalamic-prefrontal activity.

Authors:  Lezio S Bueno-Junior; José E Peixoto-Santos; Rafael N Ruggiero; Milton A V Ávila; Danilo B Marques; Cleiton Lopes-Aguiar; João P Leite
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

7.  Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy.

Authors:  Raquel A Do Val-da Silva; Jose E Peixoto-Santos; Ludmyla Kandratavicius; Jana B De Ross; Ingrid Esteves; Bruno S De Martinis; Marcela N R Alves; Renata C Scandiuzzi; Jaime E C Hallak; Antonio W Zuardi; Jose A Crippa; Joao P Leite
Journal:  Front Pharmacol       Date:  2017-03-17       Impact factor: 5.810

8.  Long-term potentiation prevents ketamine-induced aberrant neurophysiological dynamics in the hippocampus-prefrontal cortex pathway in vivo.

Authors:  Cleiton Lopes-Aguiar; Rafael N Ruggiero; Matheus T Rossignoli; Ingrid de Miranda Esteves; José Eduardo Peixoto-Santos; Rodrigo N Romcy-Pereira; João P Leite
Journal:  Sci Rep       Date:  2020-04-28       Impact factor: 4.379

9.  Muscarinic and nicotinic modulation of thalamo-prefrontal cortex synaptic plasticity [corrected] in vivo.

Authors:  Lezio Soares Bueno-Junior; Cleiton Lopes-Aguiar; Rafael Naime Ruggiero; Rodrigo Neves Romcy-Pereira; João Pereira Leite
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

10.  NMDA Receptor Antagonists for Treatment of Depression.

Authors:  Zeynep Ates-Alagoz; Adeboye Adejare
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.